N. Carpentier

Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: a prospective observational study in daily clinical practice

J. Cayuela, P. Zunic, F. Huguet, 2019, British journal of haematology.

Nilotinib after imatinib first‐line: a real‐life longitudinal cohort of patients with chronic myeloid leukaemia in chronic phase

P. Cony-Makhoul, M. Berger, V. Coiteux, 2018, British journal of haematology.

Impact of ELN recommendations in the management of first‐line treated chronic myeloid leukaemia patients: a French cross‐sectional study

P. Cony-Makhoul, M. Tulliez, F. Nicolini, 2016, British journal of haematology.

[Methotrexate and non-steroidal anti-inflammatory agent combination in rheumatoid arthritis].

B. Bannwarth, P. Vergne, J. Dehais, 1997, Therapie.

Long-term cyclosporin continuation rates in rheumatoid arthritis patients.

M. Druet‐Cabanac, P. Vergne, P. Bertin, 1999, Revue du rhumatisme.

Influence of biological variables upon pharmacokinetic parameters of intramuscular methotrexate in rheumatoid arthritis.

P. Marquet, C. Sabot, J. Debord, 1998, International journal of clinical pharmacology and therapeutics.